Create account

Coverage dated July 11, 2023

Illumina Hit With Record $476 Million Fine for Closing Grail Deal Without EU Approval

Headline from NBC New York

The European Commission last year blocked Illumina’s $7.1 billion acquisition of Grail over concerns it would stifle innovation and consumer choice.

NBC New York's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.

Read the reports

Reports & sources

9 articles, oldest first.

  1. NBC New York

    Illumina Hit With Record $476 Million Fine for Closing Grail Deal Without EU Approval (opens NBC New York)

    Published

    NBC New York's feed description

    The European Commission last year blocked Illumina’s $7.1 billion acquisition of Grail over concerns it would stifle innovation and consumer choice.

  2. Investopedia

    EU Fines Illumina Record $476 Million for Closing Grail Deal Without Approval (opens Investopedia)

    Published

    Investopedia's feed description

    The European Commission fined biotech firm Illumina 432 million euros ($476 million) for closing its acquisition of Grail without the commission's approval, in the Commission's largest merger regulation fine yet.

  3. UPI

    EU fines Illumina $476 million for jumping gun in takeover of GRAIL (opens UPI)

    Published

    UPI's feed description

    The European Union hit U.S. biotech company Illumina with a record $476 million fine Wednesday for going ahead with its takeover of cancer-test developer GRAIL despite the deal being placed on hold and eventually blocked

  4. Wall Street Journal

    Illumina Fined More Than $400 Million in Europe for Closing Grail Deal Early (opens Wall Street Journal)

    Published

    Wall Street Journal's feed description

    The European Union’s antitrust watchdog called the move to wrap up the acquisition during an in-depth probe an unprecedented infringement. Illumina said it would appeal the fine.

  5. The Boston Globe

    EU fines US firm Illumina $475m on buying cancer-screening company Grail without approval (opens The Boston Globe)

    Published

    The Boston Globe's feed description

    “This is a very serious infringement,” EU antitrust Commissioner Margrethe Vestager said.

  6. Forbes

    Illumina Fined $476 Million For Acquiring Cancer Test Maker Grail Without EU Approval (opens Forbes)

    Published

    Forbes's feed description

    The record antitrust fine from the EU comes months after the FTC ordered the company to divest its $7.1 billion acquisition of Grail.

Identical headlines usually mean shared wire copy. They are counted as separate articles but are not independent confirmation.

Illumina Hit With Record $476 Million Fine for Closing Grail Deal Without EU Approval | Since Then